Latest Conference Articles

February 20th 2017, 11:45pm

Genitourinary Cancers Symposium (ASCO GU)

Fred Saad, MD, professor and chairman of Urology, director of Genitourinary Oncology, the University of Montreal Hospital Centers, discusses recent updates in active surveillance for patients with prostate cancer.

February 20th 2017, 8:37pm

Genitourinary Cancers Symposium (ASCO GU)

Thomas Powles, MD, Barts Cancer Institute, discusses durvalumab as a second-line therapy in locally advanced and metastatic urothelial cancer.

February 19th 2017, 4:18am

Genitourinary Cancers Symposium (ASCO GU)

Five of 8 patients with metastatic urothelial cancer benefited from the combination of ipilimumab and nivolumab after having no response to single-agent nivolumab.

February 19th 2017, 3:46am

Genitourinary Cancers Symposium (ASCO GU)

Combining the PD-1 inhibitor pembrolizumab with chemotherapy induced objective responses in one-third of patients with previously treated metastatic urothelial carcinoma.

February 18th 2017, 10:44pm

Genitourinary Cancers Symposium (ASCO GU)

Eric Jonasch, MD, professor, The University of Texas MD Anderson Cancer Center, discusses the promise of immuno-oncology agents in sarcomatoid renal cell carinoma (RCC).

February 18th 2017, 10:40pm

Genitourinary Cancers Symposium (ASCO GU)

Gary Steinberg, MD, director, Urologic Oncology, The University of Chicago Medicine, discusses the immune response results of vesigenurtacel-I (HS-410) vaccine in non-muscle invasive bladder cancer (NMIBC).

February 18th 2017, 10:36pm

Genitourinary Cancers Symposium (ASCO GU)

Michael J. Morris, MD, Memorial Sloan Kettering Cancer Center, discusses bone biomarkers for radium-223 dichloride (Xofigo) in castration-resistant prostate cancer.

February 18th 2017, 8:29am

Genitourinary Cancers Symposium (ASCO GU)

The PD-L1 inhibitor durvalumab demonstrated compelling clinical activity and a manageable safety profile as second-line therapy for locally advanced or metastatic urothelial cancer.

February 18th 2017, 7:10am

Genitourinary Cancers Symposium (ASCO GU)

The genomic-based Decipher test effectively predicted metastasis and prostate cancer-specific mortality from diagnostic biopsy specimens for patients with intermediate- and high-risk prostate cancer.

February 18th 2017, 2:38am

Genitourinary Cancers Symposium (ASCO GU)

Arjun Balar, MD, director, Genitourinary Medical Oncology Progam, NYU Langone Medical Center, discusses the results from the KEYNOTE-053 trial in cisplatin-ineligible advanced urothelial carcinoma.

February 17th 2017, 10:44pm

Genitourinary Cancers Symposium (ASCO GU)

According to preliminary results from an ongoing trial, half of a small group of patients with metastatic castration-resistant prostate cancer had a PSA response during treatment with the PD-L1 inhibitor durvalumab and the PARP inhibitor olaparib (Lynparza).

February 17th 2017, 9:59pm

Genitourinary Cancers Symposium (ASCO GU)

According to results of a prospective clinical study, circulating tumor cell mRNA of full-length androgen receptor (AR) correlated with detection of the AR-V7 variant and with response to AR-targeted therapy for castration-resistant prostate cancer.

February 17th 2017, 9:33pm

Genitourinary Cancers Symposium (ASCO GU)

William Oh, MD, professor, Mount Sinai Hospital, discusses the results from a trial that compared second-line chemotherapy to alternative androgen receptor-targeted agents (ARTA) in patients with metastatic castration-resistant prostate cancer (mCRPC).

February 17th 2017, 7:34pm

Genitourinary Cancers Symposium (ASCO GU)

Josh Armenia, PhD, Memorial Sloan Kettering Cancer Center, discusses the results of an analysis of significantly mutated genes in prostate cancer.

February 17th 2017, 2:50am

Genitourinary Cancers Symposium (ASCO GU)

Andrea B. Apolo, MD, chief of bladder cancer section, National Cancer Institute, discusses the phase I study of cabozantinib (Cabometyx) plus nivolumab (Opdivo) and ipilimumab (Yervoy) in patients with refractory metastatic urothelial carcinoma (mUC) and other genitourinary tumors.

February 17th 2017, 1:18am

Genitourinary Cancers Symposium (ASCO GU)

Hans Hammers, MD, PhD, associate professor, Internal Medicine, UT Southwestern Medical Center, discusses HyperAcute Renal (HAR) immunotherapy in patients with renal cell carcinoma (RCC).

February 16th 2017, 10:48pm

Genitourinary Cancers Symposium (ASCO GU)

Scott T. Tagawa, MD, Weill Cornell Medicine/New York-Presbyterian, discusses updated results from the IMMU-132 trial in metastatic urothelial cancer (mUC).

February 14th 2017, 3:21am

Genitourinary Cancers Symposium (ASCO GU)

Up to 94% of patients with metastatic castration-resistant prostate cancer have circulating tumor DNA with at least 1 genetic alteration, suggesting ctDNA could be a noninvasive alternative to traditional tumor biopsies and help personalize treatment in this setting.

February 14th 2017, 3:12am

Genitourinary Cancers Symposium (ASCO GU)

Use of antibiotics up to a month before treatment with a checkpoint inhibitor may decrease the efficacy of the immunotherapy agent, results of a retrospective analysis show.

February 14th 2017, 2:59am

Genitourinary Cancers Symposium (ASCO GU)

Some patients who had to stop their PD-1/PD-L1 immunotherapy because of an immune-related adverse event proved to be sustained responders, even after being off the therapy for more than 6 months.